Physician profile
Paul Haney
NPI 1649376542
$10,350.94
in general payments reported to CMS, 2019-2025
19 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,255 · 2020: $3,131 · 2021: $12.71 · 2022: $2,279 · 2023: $291 · 2024: $77.04 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,755.21 | 2019-2024 | Da Vinci Surgical System |
| Ethicon US, LLC | $138.14 | 2020-2023 | Linx Reflux Management System, Enseal |
| Covidien LP | $59.67 | 2020 | |
| Ardelyx, INC. | $58.66 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $55.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $48.81 | 2025 | Voquezna |
| Abbvie INC. | $30.96 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.86 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $20.47 | 2025 | Entyvio |
| Janssen Biotech, INC. | $20.26 | 2025 | Tremfya |
| Pacira Pharmaceuticals Incorporated | $19.65 | 2025 | Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $19.13 | 2024 | |
| Averitas Pharma INC. | $17.67 | 2025 | Qutenza |
| Shire North American Group INC | $16.40 | 2019 | |
| Smith+Nephew, INC. | $15.77 | 2025 | Collagenase Santyl |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reprise Biomedical, INC. | $13.91 | 2020 | |
| Exact Sciences Corporation | $13.67 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $13.64 | 2025 | Wegovy |
| Davol INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.